☆ 4.7 Meeting Abstract

A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)

ANNALS OF ONCOLOGY (2018)

Add to Collection

Journal

ANNALS OF ONCOLOGY
Volume 29, Issue -, Pages -

Publisher

OXFORD UNIV PRESS

Keywords

-

Categories

Oncology

Funding

  1. Ludwig Institute for Cancer Research, Cancer Research Institute
  2. VentiRx
  3. Medimmune
  4. NIH/NCI [P30 CA008748]

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.